BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Suven Life Sciences Ltd Q1 PAT Up by 274% to Rs.29.77 Cr


8/13/2013 8:36:26 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HYDERABAD, INDIA (13 Aug’ 2013) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, and Contract Research and Manufacturing Services ( CRAMS) company today announced its un-audited financial results for the quarter ended 30th Jun 2013. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13th Aug 2013 at Hyderabad.

Financial Highlights for the 1st Quarter ended Jun’ 2013:

Growth in revenue Rs 1118 Mn vs.Rs 711 Mn - Up by 57%

Growth in PAT Rs 298 Mn vs. Rs 79 Mn - Up by 274%

Growth in EBIDTA Rs 462 Mn vs. Rs 139 Mn - Up by 233%

The growth in profit was a result of the commercialization of 2 products under CRAMS and also due to increased sales volume of 2 of the regular products.

Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 79 Mn (7.10% on revenue) for the Qtr ended June’ 2013.

A Dividend of Re 0.30 per share (30% of face value of Rs.1.00 each) for the accounting year 2012-13 has been approved in AGM held on 13th Aug ‘2013.

During the quarter there were major qualitative achievements with the grant of 16 (sixteen) product patents to Suven’s drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES